Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
A legfontosabb adatok
- Ki végzi
- Istanbul University
- Hol
- Törökország1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 44 fő vett részt
- Kezdés
- 2023. jún. 1.
- Befejezés
- 2026. febr. 15.
- A vizsgálat típusa
- Megfigyeléses, 3 csoport
- A regiszteradat frissítve
- 2026. július 13.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 5 feltétel megnézéseKevesebb
Ki vehet részt
- Having a diagnosis of primary membranous nephropathy (patient group)
- Having a diagnosis of primary IgA nephropathy (diseased control group)
- Being healthy (healthy control group)
- Agreeing to participate in the research (informed consent)
Ki nem vehet részt
- Refusing to participate in the research
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The aim of this observational study is to provide analysis of T and B lymphocyte subgroups in peripheral blood samples of patients with primary membranous nephropathy (MN). A search for disease-related circulating antibodies [anti-phospholipase A2 receptor antibody (anti-PLA2R) and anti-thrombospondin type 1 domain-containing 7A antibody (anti-THSD7A)] in patients' sera is also planned.
A teljes eredeti leírásKevesebb
The main questions to answer are:
1. What is the relationship of these cell populations and their distribution during follow-up with treatment, treatment responses, and relapses? 2. What is the relationship of the cell populations with anti-PLA2R (or anti-THSD7A) antibody levels?
Participants will provide peripheral venous blood samples at pre-designated regular intervals.
The research team will compare results of the primary MN group with two control groups (IgA nephropathy and healthy volunteer groups) to see if the findings are specific for primary MN.
A vizsgálat 3 csoportja
- Study Group (Primary Membranous Nephropathy)
Patients with biopsy-proven primary membranous nephropathy will be included (n=18). Samples will be collected from patients diagnosed with primary MN before starting conventional immunosuppressive therapy with calcineurin inhibitors (CNI) and corticosteroids (CS) and at 3, 6, 12, 18 and 24 months after starting the treatment. In case of failure after treatment with CNIs and CS treatment, rituximab (RTX) is used. If patient switches to RTX, samples will be taken before and 1, 3, 6, 12, 18, and 24 months after the first dose of RTX. If relapse occurs, sampling will be done regardless of the timing. Treatment decisions will solely be made in line with the guidelines, and there will be no intervention.
- Control Group 1 (IgA Nephropathy)
After the patient group sampling is completed, a diseased control group will be formed from patients with primary IgA nephropathy according to the distribution of age and sex (n=12). Samples will be collected from the patients for one time only (cross-sectional sampling).
- Control Group 2 (Healthy Volunteers)
After the patient group sampling is completed, a healthy control group will be formed from healthy volunteers according to the distribution of age and sex (n=14). Samples will be collected from healthy volunteers for one time only (cross-sectional sampling).
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Analysis of T- and B-Cell Subpopulations in Patients With Primary Membranous Nephropathy
- A regiszteradat frissítve
- 2026. július 13.